Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, French pharmaceutical giant sanofi-aventis (NYSE:SNY) has earned a respected four-star ranking.

With that in mind, let's take a closer look at sanofi's business and see what CAPS investors are saying about the stock right now.

Sanofi-aventis facts

Headquarters (Founded)

Paris (1970)

Market Cap

$84.9 Billion



Trailing-12-Month Revenue

$42.21 Billion


CEO Christopher Viehbacher (Since September 2008)

CFO Jermoe Contamine (Since March 2009)

Compound Annual Growth, Revenue, and Net Income (Past Five Years)

27.5% and 13.1%

Dividend Yield, Trailing



Pfizer (NYSE:PFE)

Merck (NYSE:MRK)

CAPS Members Bullish on SNY Also Bullish on

Johnson & Johnson (NYSE:JNJ)

Procter & Gamble (NYSE:PG)

CAPS Members Bearish on SNY Also Bearish on

Citigroup (NYSE:C)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 741 of the 784 members who have rated sanofi-aventis -- 94.5% -- believe the stock will outperform the S&P 500 going forward. These bulls include VUCommodore and NASDAQNH.

Just last month, VUCommodore singled out sanofi-aventis as an Oracle-owned income opportunity: "This [Berkshire Hathaway (NYSE:BRK-A)] holding boasts a substantial dividend yield, and has the necessary financial strength to weather a short to medium term 'double dip' in the economy."

In a pitch from two weeks later, NASDAQNH elaborates. Here's an excerpt:

Sanofi has a very favorable market price compared to the free cash flow it generates from operation income. The growth is moderate, but has not been affected doing the recession. Yet the price is floating around 25-35% below what it was a few years ago. ... Only 33% of revenue is generated from the US, which means Sanofi would be less affected by the Obama health care plan. It also gives US investors an excellent opportunity to protect their assets, if they believe the USD will come under pressure.

What do you think about sanofi-aventis, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so get started!